EDAP Aligns Management Team to Maximize Global Opportunities
31 May 2012 - 10:00PM
– CEO Marc Oczachowski Established in U.S. –
– CFO Eric Soyer Named General Manager, EDAP TMS
France –
– CEO EDAP TMS Japan Jean-François Bachelard
Named EDAP Asia Operations Supervisor –
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, has aligned its management team to focus on the U.S.
opportunities for both its Ablatherm® High Intensity Focused
Ultrasound (HIFU), and its newest extracorporeal shockwave
lithotripsy (ESWL) platform, the Sonolith® i-move.
Marc Oczachowski, Chief Executive Officer of EDAP TMS, has now
located to the U.S. and Eric Soyer, the Company's Chief Financial
Officer, has been named General Manager of EDAP TMS France. In
addition to his current responsibilities, Mr. Soyer will head
operations of the Company's main subsidiary in Lyon, France, which
covers the group's supply chain, industry and administration, and
research and development departments. Jean Francois
Bachelard, currently CEO of subsidiary EDAP TMS Japan, has been
named Asia Operations Supervisor and will head the Company's
Malaysia and Korea subsidiaries in addition to EDAP TMS Japan.
"After careful consideration, the Board came to the conclusion
that the U.S. market is critically important for EDAP," said
Philippe Chauveau, Chairman of the Board of Directors of EDAP
TMS. "We see significant growth drivers in the U.S., both in
the lithotripsy market and in continuing to drive our
Ablatherm-HIFU program toward FDA submission, targeted for fourth
quarter 2012. With Marc headquartered in the U.S., we believe
that EDAP will be better able to seize these opportunities and
increase shareholder value."
Marc Oczachowski said, "There are clear milestones and important
challenges for EDAP in the U.S., and it is crucial that we
concentrate our efforts on seizing these opportunities. My
presence in the U.S. will assure that I am an integral part of the
team working to advance our Ablatherm-HIFU submission to the FDA
and focusing on accelerating our sales and marketing initiatives to
aggressively penetrate the ESWL market."
Mr. Oczachowski continued, "I will be able to focus a great
majority of my time and efforts on our U.S. priorities and
opportunities, as I know I can count on a very solid and
professional team in both Europe and Asia to continue working on
our projects and growth initiatives outside of the U.S."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm®, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment
is shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate
cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is
currently undergoing evaluation in a multi-center U.S. Phase II/III
clinical trial under an Investigational Device Exemption (IDE)
granted by the FDA, the ENLIGHT U.S. clinical study. The
Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment (the Sonolith® range)
for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. These include statements regarding the
Company's growth and expansion plans, the conclusiveness of the
results of and success of its Ablatherm-HIFU clinical trials and
expectations regarding the IDE submission to and approval by the
FDA of the Ablatherm-HIFU device. Such statements are based on
management's current expectations and are subject to a number of
uncertainties, including the uncertainties of the regulatory
process, and risks that could cause actual results to differ
materially from those described in these forward-looking
statements. Factors that may cause such a difference include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form
20-F. Ablatherm-HIFU treatment is in clinical trials, but not
FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024